- Home
- ARVN
ARVN
Arvinas Inc.
as 10-27-2025 9:35am EST
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
| Founded: | 2015 | Country: | United States |
| Employees: | 430 | City: | NEW HAVEN |
| Market Cap: | 676.2M | IPO Year: | 2018 |
| Target Price: | $17.61 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Buy | Number of Analysts: | 23 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.90 - $29.61 | Next Earning Date: | 11-04-2025 |
| Revenue: | $372,800,000 | Revenue Growth: | 299.57% |
| Revenue Growth (this year): | 1.01% | Revenue Growth (next year): | -54.37% |
Stock Insider Trading Activity of Arvinas Inc. (ARVN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Morrison Briggs | ARVN | Director | Sep 22 '25 | Buy | $7.57 | 30,000 | $227,010.00 | 76,021 |
Latest Arvinas Inc. News
ARVN Breaking Stock News: Dive into ARVN Ticker-Specific Updates for Smart Investing
GlobeNewswire
14 days ago
Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress
MT Newswires
21 days ago
Sector Update: Health Care Stocks Edge Higher Pre-Bell Monday
GlobeNewswire
22 days ago
Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
Zacks
4 months ago
Wall Street Analysts Believe Arvinas (ARVN) Could Rally 89.85%: Here's is How to Trade
MT Newswires
4 months ago
Arvinas Says ARV-393 Preclinical Studies Show 'Significant' Single-Agent Activity in Certain Lymphoma
GlobeNewswire
4 months ago
Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress
MT Newswires
5 months ago
Sector Update: Health Care Stocks Advance Premarket Friday
MT Newswires
5 months ago
Arvinas, Pfizer Submit New Drug Application for Vepdegestrant as Breast Cancer Treatment
Compare ARVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARVN Arvinas Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.